Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)

Hematological Oncology - United Kingdom
doi 10.1002/hon.2437_58
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents

Haematologica
Hematology
2019English

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Inhibition of IgE-mediated Secretion From Human Basophils With a Highly Selective Bruton's Tyrosine Kinase, Btk, Inhibitor

International Immunopharmacology
AllergyImmunologyPharmacology
2011English

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2016English

Waldenström Macroglobulinemia

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy